# Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis

> **NCT00124943** · PHASE1,PHASE2 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 112 (actual)

## Conditions studied

- Coronary Restenosis

## Interventions

- **DRUG:** Nanoparticle Paclitaxel

## Key facts

- **NCT ID:** NCT00124943
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2012-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124943, "Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00124943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*